Grupo de Estudo de Cardio-Oncologia

🫀Fluoropyrimidines induced #cardiotoxicity, what is new? by Prof @dr_manisty at #ESCardioOnco26: 📍~30% of solid tumour regimens contain fluoropyrimidines 📍>2 million patients receive 5-FU/#capecitabine annually 📍#Fluoropyrimidines are the 2nd most common cause of cancer drug-related cardiac death 📍Symptoms often occur early, with a peak onset around 3 days after treatment initiation 📍Baseline CV risk assessment remains essential before starting therapy 📍Consider CAD screening in selected high/very-high-risk patients 📍Coronary vasospasm is the most common presentation, but MI can occur 📍Rechallenge may be possible in carefully selected patients after MDT discussion, exclusion of severe CAD, & initiation of prophylactic anti-anginal therapy #CardioOncology #Cardiotoxicity @escardio